JP2015212307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015212307A5 JP2015212307A5 JP2015164731A JP2015164731A JP2015212307A5 JP 2015212307 A5 JP2015212307 A5 JP 2015212307A5 JP 2015164731 A JP2015164731 A JP 2015164731A JP 2015164731 A JP2015164731 A JP 2015164731A JP 2015212307 A5 JP2015212307 A5 JP 2015212307A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorotoxin
- seq
- amino acid
- tumor
- chlorotoxin polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710164760 Chlorotoxin Proteins 0.000 claims 56
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 claims 56
- 229960005534 chlorotoxin Drugs 0.000 claims 56
- 229920001184 polypeptide Polymers 0.000 claims 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 125000000539 amino acid group Chemical group 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 230000005298 paramagnetic effect Effects 0.000 claims 10
- 150000002500 ions Chemical class 0.000 claims 9
- 230000002285 radioactive effect Effects 0.000 claims 9
- 239000004472 Lysine Substances 0.000 claims 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 7
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000032612 Glial tumor Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 239000010949 copper Substances 0.000 claims 4
- 238000003384 imaging method Methods 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims 2
- 229910052765 Lutetium Inorganic materials 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 201000005969 Uveal melanoma Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims 2
- 229910052789 astatine Inorganic materials 0.000 claims 2
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001886 ciliary effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 229910052738 indium Inorganic materials 0.000 claims 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims 2
- 208000030173 low grade glioma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002575 ocular melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000028591 pheochromocytoma Diseases 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 201000003708 skin melanoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 229910052716 thallium Inorganic materials 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 108010016626 Dipeptides Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- YCKRFDGAMUMZLT-IGMARMGPSA-N Fluorine-19 Chemical compound [19F] YCKRFDGAMUMZLT-IGMARMGPSA-N 0.000 claims 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims 1
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 claims 1
- 229910052772 Samarium Inorganic materials 0.000 claims 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000005082 bioluminescent agent Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 1
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 claims 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000005081 chemiluminescent agent Substances 0.000 claims 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- IOIFRTZBJMZZFO-UHFFFAOYSA-N dysprosium(3+) Chemical compound [Dy+3] IOIFRTZBJMZZFO-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 claims 1
- 229910052733 gallium Inorganic materials 0.000 claims 1
- 229940006110 gallium-67 Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 229940055742 indium-111 Drugs 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 229940044173 iodine-125 Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims 1
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 claims 1
- 230000005291 magnetic effect Effects 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229940097886 phosphorus 32 Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000002096 quantum dot Substances 0.000 claims 1
- 229910052702 rhenium Inorganic materials 0.000 claims 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims 1
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 claims 1
- 125000006850 spacer group Chemical group 0.000 claims 1
- 229910052713 technetium Inorganic materials 0.000 claims 1
- 229940056501 technetium 99m Drugs 0.000 claims 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 claims 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 claims 1
- BKVIYDNLLOSFOA-OIOBTWANSA-N thallium-201 Chemical compound [201Tl] BKVIYDNLLOSFOA-OIOBTWANSA-N 0.000 claims 1
- -1 trimethyl group Chemical group 0.000 claims 1
- AWSFICBXMUKWSK-UHFFFAOYSA-N ytterbium(3+) Chemical compound [Yb+3] AWSFICBXMUKWSK-UHFFFAOYSA-N 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30161510P | 2010-02-04 | 2010-02-04 | |
| US61/301,615 | 2010-02-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552126A Division JP5858932B2 (ja) | 2010-02-04 | 2011-02-04 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016201676A Division JP6181265B2 (ja) | 2010-02-04 | 2016-10-13 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015212307A JP2015212307A (ja) | 2015-11-26 |
| JP2015212307A5 true JP2015212307A5 (https=) | 2016-04-21 |
| JP6027200B2 JP6027200B2 (ja) | 2016-11-16 |
Family
ID=44355816
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552126A Active JP5858932B2 (ja) | 2010-02-04 | 2011-02-04 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| JP2015164731A Active JP6027200B2 (ja) | 2010-02-04 | 2015-08-24 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| JP2016201676A Active JP6181265B2 (ja) | 2010-02-04 | 2016-10-13 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552126A Active JP5858932B2 (ja) | 2010-02-04 | 2011-02-04 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016201676A Active JP6181265B2 (ja) | 2010-02-04 | 2016-10-13 | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9018347B2 (https=) |
| EP (2) | EP2531206B1 (https=) |
| JP (3) | JP5858932B2 (https=) |
| KR (1) | KR101923235B1 (https=) |
| CN (2) | CN106995493B (https=) |
| AU (1) | AU2011213678B2 (https=) |
| CA (1) | CA2788824C (https=) |
| CY (1) | CY1119276T1 (https=) |
| DK (1) | DK2531206T3 (https=) |
| ES (1) | ES2638871T3 (https=) |
| HR (1) | HRP20171291T1 (https=) |
| HU (1) | HUE034119T2 (https=) |
| IL (1) | IL221278B (https=) |
| LT (1) | LT2531206T (https=) |
| PL (1) | PL2531206T3 (https=) |
| PT (1) | PT2531206T (https=) |
| RS (1) | RS56231B1 (https=) |
| SI (1) | SI2531206T1 (https=) |
| SM (1) | SMT201700418T1 (https=) |
| WO (1) | WO2011097533A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE502048T1 (de) | 2005-04-22 | 2011-04-15 | Univ Washington | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
| US8227439B2 (en) | 2008-05-15 | 2012-07-24 | Morphotek, Inc. | Treatment of metastatic tumors |
| JP5858932B2 (ja) * | 2010-02-04 | 2016-02-10 | モルフォテック， インコーポレイテッド | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| JP2013532126A (ja) * | 2010-05-11 | 2013-08-15 | フレッド ハッチンソン キャンサー リサーチ センター | クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法 |
| AU2013204119B2 (en) * | 2010-05-11 | 2016-03-31 | Fred Hutchinson Cancer Center | Chlorotoxin variants, conjugates, and methods for their use |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| CN105008393A (zh) | 2012-12-10 | 2015-10-28 | 弗莱德哈钦森癌症研究中心 | 用于筛选的方法 |
| US9784730B2 (en) | 2013-03-21 | 2017-10-10 | University Of Washington Through Its Center For Commercialization | Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine |
| EP3046572B1 (en) | 2013-09-17 | 2025-07-30 | Blaze Bioscience, Inc. | Chlorotoxin conjugates and methods of use thereof |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| CN105801706B (zh) * | 2014-12-31 | 2019-10-22 | 深圳先进技术研究院 | 蝎氯毒素多肽-铁蛋白重链融合蛋白、自组装蛋白质纳米笼及其制备方法和应用 |
| CN104877016A (zh) * | 2015-04-30 | 2015-09-02 | 温州生物材料与工程研究所 | 折叠氯代毒素、氯代毒素变异体与折叠氯代毒素变异体及其制备工艺 |
| WO2016210376A2 (en) * | 2015-06-26 | 2016-12-29 | Fred Hutchinson Cancer Research Center | Therapeutic peptides and methods of use thereof |
| US11090358B2 (en) | 2015-09-09 | 2021-08-17 | Fred Hutchinson Cancer Research Center | Cartilage-homing peptides |
| CA3001833A1 (en) | 2015-10-13 | 2017-04-20 | City Of Hope | Chimeric antigen receptors containing a chlorotoxin domain |
| WO2017136769A1 (en) | 2016-02-04 | 2017-08-10 | Eisai R&D Management Co., Ltd. | Peptide drug conjugates |
| WO2017181149A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| EP3442555A4 (en) * | 2016-04-15 | 2020-04-01 | Blaze Bioscience, Inc. | METHOD FOR TREATING BREAST CANCER |
| KR101678393B1 (ko) | 2016-08-25 | 2016-12-06 | (주)넥스젠바이오텍 | 피부 세포 증식 효과가 증가한 전갈독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선, 피부 탄력 증대 및 항노화 화장료 조성물 |
| KR102618373B1 (ko) * | 2016-12-09 | 2023-12-29 | 유에이비 리서치 파운데이션 | 키메라성 클로로톡신 수용체 |
| AU2018210157B2 (en) | 2017-01-18 | 2022-10-06 | Fred Hutchinson Cancer Center | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
| EP3595699A4 (en) | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE |
| AU2018283161A1 (en) | 2017-06-15 | 2020-01-02 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
| EP3681540A4 (en) | 2017-09-15 | 2021-05-19 | Eisai, Inc. | CHLOROTOXIN AGENT AND USES THEREOF |
| EP3727146A4 (en) | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE |
| US20220233694A1 (en) * | 2019-05-31 | 2022-07-28 | The Cleveland Clinic Foundation | Functionalized fullerene gel tumor treatment |
| EP4271702B1 (en) * | 2020-12-30 | 2024-11-06 | VRG Therapeutics Zrt. | Chlorotoxin derivatives and use thereof |
| CN113092609B (zh) * | 2021-03-31 | 2022-03-29 | 中国海洋大学 | 一种Gymnodimine毒素标准物质的制备方法 |
| CN113527416A (zh) * | 2021-08-11 | 2021-10-22 | 南开大学 | 一种硝基还原酶响应氨基酸及肿瘤乏氧荧光探针的制备方法 |
| KR20240015034A (ko) * | 2022-07-25 | 2024-02-02 | 충남대학교산학협력단 | Stichodactyla 독소 분비를 위한 재조합 발현 벡터및 이로 형질전환된 약독화 살모넬라 균주 |
| CN118767156B (zh) * | 2023-04-10 | 2025-11-21 | 湖南中晟全肽生物科技股份有限公司 | 一种氯毒素类似物的多肽偶联物及其用途 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| DE3407582A1 (de) | 1984-03-01 | 1985-09-05 | Dornier System Gmbh, 7990 Friedrichshafen | Schaltungsanordnung fuer einen regelkreis |
| EP0282581A4 (en) | 1986-09-19 | 1988-11-02 | Scripps Clinic Res | Monoclonal paratopic molecule directed to human ganglioside gd2. |
| US5171749A (en) | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
| US5591829A (en) | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5051364A (en) | 1989-02-16 | 1991-09-24 | The Salk Institute For Biological Studies | Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies |
| DE3909799A1 (de) | 1989-03-24 | 1990-09-27 | Behringwerke Ag | Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung |
| US5173504A (en) | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5171741A (en) | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5308608A (en) | 1989-06-07 | 1994-05-03 | University Of British Columbia | Photosensitizing Diels-Alder porphyrin derivatives |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| US5223253A (en) | 1989-09-28 | 1993-06-29 | American Home Products Corporation | Bovine vaccine compositions and method for preventing trichomonas infections using same |
| GB2250993B (en) | 1990-11-21 | 1995-02-15 | Inst Nat Sante Rech Med | Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| MX9205293A (es) | 1991-09-20 | 1993-05-01 | Syntex Sinergen Neuroscience J | Factores neurotrofico derivado del glial |
| US5314992A (en) | 1991-11-25 | 1994-05-24 | Trustees Of Dartmouth College | Lipocortin-1 receptor protein and its uses |
| EP0642353A1 (en) | 1992-05-14 | 1995-03-15 | Oncologix, Inc. | Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors |
| US5726304A (en) | 1992-10-30 | 1998-03-10 | The University Of British Columbia | Porphocyanine and CNC-expanded porphyrins |
| US5405957A (en) | 1992-10-30 | 1995-04-11 | The University Of British Columbia | Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use |
| UA29466C2 (uk) | 1993-01-14 | 2000-11-15 | Канзер Рісерч Кампейн Технолоджі, Лтд | Фармацевтична композиція з антипухлинною активністю |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5688773A (en) | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
| US5648485A (en) | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
| US5985822A (en) | 1994-12-09 | 1999-11-16 | The Scripps Research Institute | Inhibition of glial cell proliferation with N-CAM homophilic peptides |
| US5756340A (en) | 1995-05-08 | 1998-05-26 | The Regents Of The University Of California | Insect control with multiple toxins |
| JP3809502B2 (ja) | 1995-05-30 | 2006-08-16 | 二郎 有川 | ハンタウィルス抗原蛋白質およびモノクローナル抗体 |
| JPH0971559A (ja) | 1995-06-29 | 1997-03-18 | Nippon Nohyaku Co Ltd | ヒドロキシルアミン誘導体及び該化合物を含有する殺菌剤 |
| JPH0971599A (ja) | 1995-09-06 | 1997-03-18 | Nippon Seibutsu Kagaku Kenkyusho | 鶏貧血ウイルス（ｃａｖ）感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン |
| US6667156B2 (en) * | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
| US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
| US6541212B2 (en) | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| DK0983273T3 (da) | 1997-05-07 | 2002-04-22 | Univ British Columbia | Ethylenglycolestere af monohydrobenzoporphyrinderivater som fotoaktive midler |
| US5880145A (en) | 1997-05-07 | 1999-03-09 | The University Of British Columbia | Class of benzoporphyrin derivative photoactive compounds |
| US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
| AU748250B2 (en) | 1997-12-05 | 2002-05-30 | Kyogo Itoh | Tumor antigen peptide derivatives |
| AU5197599A (en) | 1998-08-12 | 2000-03-06 | Daiichi Pure Chemicals Co., Ltd. | Fluorescent labelling reagents |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6767635B1 (en) | 1999-09-14 | 2004-07-27 | Biomedical Apherese Systeme Gmbh | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
| US6623936B1 (en) | 1999-09-24 | 2003-09-23 | Imgenex | Compositions and methods for improved detection and classification of neoplasms |
| AU4305101A (en) | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
| DE10020376A1 (de) | 2000-04-26 | 2001-11-08 | Inst Zelltechnologie E V | Dynamische Marker |
| CA2427858A1 (en) | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| WO2002069896A2 (en) | 2001-03-01 | 2002-09-12 | Northwest Hospital | Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation |
| WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| WO2003000203A2 (en) | 2001-06-26 | 2003-01-03 | Uab Research Foundation | Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling |
| CA2453603C (en) | 2001-07-16 | 2007-01-02 | Maytag Corporation | Method and system for refrigerator with integrated presentation mode |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US6972326B2 (en) | 2001-12-03 | 2005-12-06 | Molecular Probes, Inc. | Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes |
| WO2003066663A2 (en) | 2002-02-04 | 2003-08-14 | Auburn University | Peptides for recognition and targeting of glial cell tumors |
| US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
| WO2003101474A1 (en) | 2002-05-31 | 2003-12-11 | Transmolecular, Inc. | Combination chemotherapy with chlorotoxin |
| US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
| US7560160B2 (en) | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
| US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| DE10328251A1 (de) | 2003-06-24 | 2005-01-13 | Toximed Gmbh | Pharmazeutischer Wirkstoff |
| WO2005053611A2 (en) | 2003-11-26 | 2005-06-16 | Transmolecular, Inc. | Treatment of phosphatidylinositol phospholipid disorders |
| US20080153746A1 (en) | 2004-04-06 | 2008-06-26 | Transmolecular, Inc. | Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers |
| DE602005019728D1 (de) | 2004-04-06 | 2010-04-15 | Transmolecular Inc | Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat |
| CA2565701A1 (en) | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| JP2008507280A (ja) | 2004-07-21 | 2008-03-13 | アンブレツクス・インコーポレイテツド | 非天然コードアミノ酸を用いた生合成ポリペプチド |
| GB0422901D0 (en) | 2004-10-14 | 2004-11-17 | Ares Trading Sa | Lipocalin protein |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
| US20070037232A1 (en) | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
| EP1871911A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Cancer-related genes (prlr) |
| WO2006110582A1 (en) | 2005-04-08 | 2006-10-19 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| ATE502048T1 (de) | 2005-04-22 | 2011-04-15 | Univ Washington | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
| CN101232903A (zh) * | 2005-04-22 | 2008-07-30 | 安姆根有限公司 | 具有延长的血液半衰期的毒素肽 |
| US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| MX2008002149A (es) | 2005-08-18 | 2008-04-22 | Ambrx Inc | Composiciones de arnt y sus usos. |
| US20070084929A1 (en) | 2005-10-17 | 2007-04-19 | Hitoshi Watanabe | Barcode reader with a music player |
| EP2147927A3 (en) | 2006-03-31 | 2010-09-01 | Transmolecular, Inc. | Use of 131i-tm-601 for the diagnosis and treatment of gliomas |
| EP2029157A4 (en) | 2006-05-19 | 2009-11-18 | Georgia Tech Res Inst | ABC TRANSPORTERLIGAND |
| CN101003788A (zh) | 2006-09-21 | 2007-07-25 | 武汉大学 | 一种蝎抗肿瘤转移肽及其制备方法和应用 |
| CN100564517C (zh) | 2006-09-21 | 2009-12-02 | 武汉大学 | 一种蝎抗神经胶质瘤肽及其制备方法和应用 |
| PE20081140A1 (es) * | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| US20090004105A1 (en) * | 2007-06-27 | 2009-01-01 | Zhen Cheng | Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin |
| CA2696303A1 (en) | 2007-08-07 | 2009-02-12 | Transmolecular, Inc. | Chlorotoxins as drug carriers |
| US20110283260A1 (en) | 2007-08-31 | 2011-11-17 | Iosemantics, Llc | Quality assurance tools for use with source code and a semantic model |
| EP2211913A4 (en) | 2007-10-12 | 2010-12-22 | Transmolecular Inc | SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS |
| US7904868B2 (en) | 2007-10-17 | 2011-03-08 | International Business Machines Corporation | Structures including means for lateral current carrying capability improvement in semiconductor devices |
| US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
| US20090124022A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
| US20090269777A1 (en) | 2007-10-19 | 2009-10-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US20090123970A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| CA2702611A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US20090176274A1 (en) | 2007-10-19 | 2009-07-09 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| US20090123946A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| CN101910845A (zh) | 2007-11-15 | 2010-12-08 | 比奥波托诊断股份公司 | 个体分子形式的生物标志的诊断用途 |
| ES2658852T3 (es) | 2008-01-18 | 2018-03-12 | Visen Medical, Inc. | Agentes de imaginología fluorescentes |
| US9308239B2 (en) | 2008-02-26 | 2016-04-12 | The Penn State Research Foundation | Methods and compositions for treatment of retinoid-responsive conditions |
| US8093060B2 (en) | 2008-02-28 | 2012-01-10 | Canon Kabushiki Kaisha | Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same |
| CN102026671B (zh) | 2008-03-14 | 2014-09-03 | Visen医药公司 | 整联蛋白靶向试剂及使用其的体内和体外成像方法 |
| CN102056617A (zh) | 2008-03-20 | 2011-05-11 | 特兰斯莫莱库拉公司 | 血管生成的抑制 |
| GB0807831D0 (en) | 2008-04-29 | 2008-06-04 | Cambridge Entpr Ltd | Agents for imaging cell death |
| CN101270158B (zh) | 2008-04-30 | 2010-12-22 | 武汉大学 | 一种靶向抗神经胶质瘤蛋白及制备方法和用途 |
| US8227439B2 (en) | 2008-05-15 | 2012-07-24 | Morphotek, Inc. | Treatment of metastatic tumors |
| JP2009300110A (ja) | 2008-06-10 | 2009-12-24 | Olympus Corp | 移植細胞の光学的検出方法又はイメージング方法 |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| JP5744723B2 (ja) | 2008-09-12 | 2015-07-08 | 日東電工株式会社 | 線維性疾患のイメージング剤 |
| US20100098637A1 (en) | 2008-09-23 | 2010-04-22 | The Regents Of The University Of Michigan | Dye-loaded nanoparticle |
| CN101381405B (zh) | 2008-09-24 | 2011-07-27 | 武汉摩尔生物科技有限公司 | 基因工程肿瘤靶向kct-w1多肽及制备方法和用途 |
| JP2010085108A (ja) | 2008-09-29 | 2010-04-15 | Nano Factory:Kk | 生体光イメージング用プローブ |
| US20100105150A1 (en) | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
| CN102791827B (zh) | 2009-11-09 | 2016-11-16 | 华盛顿大学商业化中心 | 官能化发色聚合物点及其生物共轭体 |
| CN101921769B (zh) | 2010-01-11 | 2012-07-25 | 山西大学 | 一种重组腺病毒及其制备方法和应用 |
| WO2011094671A2 (en) | 2010-01-29 | 2011-08-04 | The Uab Research Foundation | N-terminally conjugated polypeptides for targeted therapy and diagnosis |
| JP5858932B2 (ja) * | 2010-02-04 | 2016-02-10 | モルフォテック， インコーポレイテッド | クロロトキシンポリペプチドおよびコンジュゲートならびにその使用 |
| CN101824084A (zh) | 2010-04-08 | 2010-09-08 | 山西大学 | 靶向性抗胶质瘤蛋白质及其应用 |
| JP2013532126A (ja) * | 2010-05-11 | 2013-08-15 | フレッド ハッチンソン キャンサー リサーチ センター | クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法 |
| NZ606584A (en) | 2010-08-16 | 2014-10-31 | Pieris Ag | Binding proteins for hepcidin |
| CN104877016A (zh) * | 2015-04-30 | 2015-09-02 | 温州生物材料与工程研究所 | 折叠氯代毒素、氯代毒素变异体与折叠氯代毒素变异体及其制备工艺 |
-
2011
- 2011-02-04 JP JP2012552126A patent/JP5858932B2/ja active Active
- 2011-02-04 US US13/577,169 patent/US9018347B2/en active Active
- 2011-02-04 EP EP11740464.0A patent/EP2531206B1/en active Active
- 2011-02-04 CA CA2788824A patent/CA2788824C/en active Active
- 2011-02-04 RS RS20170847A patent/RS56231B1/sr unknown
- 2011-02-04 KR KR1020127023002A patent/KR101923235B1/ko active Active
- 2011-02-04 PL PL11740464T patent/PL2531206T3/pl unknown
- 2011-02-04 AU AU2011213678A patent/AU2011213678B2/en active Active
- 2011-02-04 HU HUE11740464A patent/HUE034119T2/en unknown
- 2011-02-04 WO PCT/US2011/023823 patent/WO2011097533A1/en not_active Ceased
- 2011-02-04 HR HRP20171291TT patent/HRP20171291T1/hr unknown
- 2011-02-04 DK DK11740464.0T patent/DK2531206T3/en active
- 2011-02-04 PT PT117404640T patent/PT2531206T/pt unknown
- 2011-02-04 LT LTEP11740464.0T patent/LT2531206T/lt unknown
- 2011-02-04 ES ES11740464.0T patent/ES2638871T3/es active Active
- 2011-02-04 SM SM20170418T patent/SMT201700418T1/it unknown
- 2011-02-04 CN CN201610856180.2A patent/CN106995493B/zh active Active
- 2011-02-04 SI SI201131279T patent/SI2531206T1/sl unknown
- 2011-02-04 EP EP17173578.0A patent/EP3238735A1/en active Pending
- 2011-02-04 CN CN201180012427.8A patent/CN102844044B/zh active Active
-
2012
- 2012-08-02 IL IL221278A patent/IL221278B/en active IP Right Grant
-
2014
- 2014-08-01 US US14/450,182 patent/US9234015B2/en active Active
-
2015
- 2015-08-24 JP JP2015164731A patent/JP6027200B2/ja active Active
- 2015-12-01 US US14/956,261 patent/US9637526B2/en active Active
-
2016
- 2016-10-13 JP JP2016201676A patent/JP6181265B2/ja active Active
-
2017
- 2017-03-23 US US15/468,085 patent/US10183975B2/en active Active
- 2017-08-30 CY CY20171100911T patent/CY1119276T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015212307A5 (https=) | ||
| Hai et al. | γ-glutamyltranspeptidase-triggered intracellular gadolinium nanoparticle formation enhances the T2-weighted MR contrast of tumor | |
| US12599684B2 (en) | Molecular probes and methods of use | |
| HRP20171291T1 (hr) | Polipeptidi i konjugati klorotoksina i njihove uporabe | |
| Herholz | Brain tumors: an update on clinical PET research in gliomas | |
| Paterson et al. | PET imaging of tumours with a 64 Cu labeled macrobicyclic cage amine ligand tethered to Tyr 3-octreotate | |
| Paterson et al. | Versatile new bis (thiosemicarbazone) bifunctional chelators: synthesis, conjugation to bombesin (7− 14)-NH2, and copper-64 radiolabeling | |
| CN111991570A (zh) | 一种FAP-α特异性肿瘤诊断SPECT显像剂 | |
| IL256649A (en) | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer | |
| JP2013518905A5 (https=) | ||
| DK2512524T3 (en) | Manganchelater and their use as contrast agents in magnetic resonance imaging (mri) | |
| WO2003020701A9 (en) | Multi-use multimodal imaging chelates | |
| CN110366432A (zh) | 基于pd-l1表达的肿瘤和免疫细胞成像 | |
| Yang et al. | A df heteronuclear complex for dual-mode phosphorescence and magnetic resonance imaging | |
| WO2020210919A1 (en) | Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy | |
| JP2021504453A (ja) | 分子イメージングのための二重標識プローブ及びその使用 | |
| JP2021502399A (ja) | 分子イメージングのための二重標識プローブ及びその使用 | |
| JP2016528299A5 (https=) | ||
| JP2011519367A5 (https=) | ||
| Park et al. | Improved tumor-targeting MRI contrast agents: Gd (DOTA) conjugates of a cycloalkane-based RGD peptide | |
| JP2012524029A5 (https=) | ||
| Tei et al. | Target visualization by MRI using the avidin/biotin amplification route: synthesis and testing of a biotin–Gd‐DOTA monoamide trimer | |
| US20240139351A1 (en) | Targeting system with improved uptake | |
| JP2012524079A5 (https=) | ||
| US9534248B2 (en) | Tumor-specific minicircles for cancer screening |